Date:	--/--/-- --:--:--
Event Id:	E5DRK9DUZ
Action Type:	ACQUISITION
Action Status:	ANNOUNCED
Acquirer Symbol:
Target Symbol:	EXAS
Updated:	--/--/-- --:--:--
Purchase Price Per Share:	105
Price Per Share Currency:	USD
News References:	https://www.businesswire.com/news/home/20260220121623/en/

Action Notes

Abbott and Exact Sciences today announced a definitive agreement for Abbott to acquire Exact Sciences, which will enable it to enter and lead in fast-growing cancer diagnostics segments, serving millions more people. Under the terms of the agreement, Exact Sciences shareholders will receive $105 per common share, representing a total equity value of approximately $21 billion. The closing is expected in the second quarter of 2026 and is subject to Exact Sciences' shareholder approval, as well as receipt of applicable regulatory approvals and other customary closing conditions. The transaction was unanimously approved by both companies' boards of directors. The EXACT Sciences special shareholder meeting to vote on the transaction will be held on 02/20. On 2/20, Exact Sciences Corporation today announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott at the special meeting of stockholders held earlier today. Subject to the satisfaction or waiver of the remaining conditions to closing, the transaction is expected to close before the end of the second calendar quarter of 2026. Under the terms of the definitive agreement with Abbott, upon completion of the transaction, Exact Sciences' stockholders will be entitled to receive $105.00 in cash, without interest and subject to any applicable withholding taxes, for each share of Exact Sciences common stock they owned as of immediately before the completion of the transaction.